Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	208,285	68,081	485,702	93,287
General and Administrative	468,027	494,963	1,455,703	989,693
Consulting and Professional Fees	220,503	87,367	428,090	473,562
Rent	15,000	16,200	45,000	43,071
Total Costs and Expenses	911,815	666,611	2,414,495	1,599,614
OPERATING LOSS	(911,815)	(666,611)	(2,414,495)	(1,599,614)
OTHER INCOME & (EXPENSES)
Interest Income	300	297	897	848
Interest Expense	(16,586)	(11,726)	(42,223)	(44,991)
Loss on Settlement of Debt through Equity Issuance below Fair Value	(28,714)	(140,000)	(42,223)	(44,991)
Loss on Settlement of Debt through Issuance of Common Shares of Regen biopharma, Inc. below fair value	(1,473,490)	(937,425)	(3,001,625)	(9,116,857)
Interest Expense attributable to amortization of discount	(6,736)	(73,387)	(154,407)	(77,419)
Preferred Shares of Regen Biopharma, Inc. issued pursuant to contractual obligations		(321)		(3,475)
Expense related to issuance of Convertible Debt to Star City				(247,500)
Total Other Income & (Expense)	(1,525,226)	(1,162,562)	(3,472,663)	(10,465,924)
NET INCOME (LOSS)	(2,437,040)	(1,829,173)	(5,887,157)	(12,065,538)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	2,050,663	1,274,739	4,544,575	8,486,861
NET INCOME (LOSS) available to common shareholders	$ (386,377)	$ (554,434)	$ (1,342,583)	$ (3,578,677)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0001)	$ (0.0001)	$ (0.0003)	$ (0.0009)
Weighted average number of shares outstanding	5,572,801,694	4,160,041,891	5,127,490,145	3,817,242,852